Advanced Soft Tissue Sarcoma Clinical Trial
Official title:
Phase 1/2, Randomized, Multicenter, Prospective Study of Gemcitabine and Rapamycin (Sirolimus) Combination Versus Gemcitabine Only to Treat Advanced Soft Tissue Sarcoma
The soft tissue sarcomas (STS) constitute an infrequent group of malignant neoplasms of
mesenchymal origin. In Spain, the approximate incidence is of 2 new cases per 100.000
inhabitants every year. In patients with metastatic STS, the average survival is very short,
approximately 12 months. The systemic treatment of the metastatic disease has had a very
limited development, with few satisfactory results. This facts reflect the urgent need to
identify new active agents for treatment of these patients.
The molecular pathway of the serine/threonine kinase mammalian target of rapamycin (mTOR)
plays a central role in the regulation of the proteins translation, cellular growth and
metabolism (Meric-Bernstam F et al. 2009). Currently, the mTOR pathway is considered a
relevant target for the development of anti-cancer drugs, as rapamycin. Preliminary results
of some clinical trials suggest that mTOR inhibitors could have some clinical activity for
different types of sarcoma, including STS (Chawla et al Proc.ASCO 2006; Schuetze et al.
Proc.ASCO 2006).
Gemcitabine is a chemotherapy antimetabolite agent with a broad antitumoral spectrum. The
activity of this drug to treat resistant sarcomas and its reduced toxicity make from
gemcitabine an adequate candidate for its study in combination with new drugs addressed to
molecular targets in the STS treatment.
Pre-clinical studies suggest that mTOR inhibitors could have a potential synergistic or
additive effect with some chemotherapy agents. The combination of rapamycin and gemcitabine
seems to be a reasonable strategy to explore for the STS treatment.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03670069 -
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
|
Phase 1 | |
| Terminated |
NCT03698227 -
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03838744 -
Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
|
Phase 2 | |
| Completed |
NCT03009201 -
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
|
Phase 1 | |
| Not yet recruiting |
NCT06370871 -
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
|
Phase 3 | |
| Recruiting |
NCT04028063 -
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
|
Phase 2 | |
| Recruiting |
NCT06062927 -
Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
|
||
| Completed |
NCT02618122 -
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece
|
||
| Completed |
NCT01975519 -
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05333458 -
Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study
|
Phase 2 | |
| Recruiting |
NCT03138161 -
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03660930 -
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
|
Phase 1/Phase 2 |